CRISPR Therapeutics AG Just Filed Its Quarterly Report: 10. Net Loss Per Sha...


10. Net Loss Per Share Attributable to Common Shareholders


Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing the net loss attributable to common shareholders by the weighted-ave rage number of common share equivalents outstanding for the period, including any dilutive effect from outstanding stock options and warrants using the treasury stock method. The Company’s net loss is net loss attributable to common shareholders for all periods presented.


The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect (in thousands):


 


 
































































 


 


Three Months Ended March 31,


 


 


 


2021


 


 


2020


 


Outstanding options


 


 


8,572,663


 


 


 


8,495,315


 


Unvested restricted common shares


 


 


1,052,379


 


 


 


967,060


 


ESPP


 


 


10,594


 


 


 



 


Total


 


 


9,635,636


 


 


 


9,462,375


 


 


 


 

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever CRISPR Therapeutics AG makes a similar move, sign up!

Other recent filings from the company include the following:

CRISPR Therapeutics AG's Chief Executive Officer just cashed-in 30,000 options - June 17, 2021
CRISPR Therapeutics AG director just disposed of 10,000 shares - June 15, 2021
CRISPR Therapeutics AG director was just granted 10,000 options - June 14, 2021
Amendments to Articles of Incorporation or - June 14, 2021
Statement of changes in beneficial ownership of securities - June 14, 2021

Auto Refresh

Feedback